1 ent, particularly since animal models representing human
AD are lacking.
2 on and composition of GABAA receptors in the human
amygdala are lacking.
3 ese impacted neural networks in primary progressive
aphasia are lacking.
4 outcome measures for clinical trials on cerebellar
ataxias are lacking.
5 thods for assessing community structure in terms of
biomass are lacking.
6 However, reliable data to estimate CVD
burden are lacking in many regions of the world, which hampers the e
7 es investigating the cellular origin of gray matter
changes are lacking.
8 ne profiling data across different clinical
characteristics are lacking.
9 potential range shifts, especially when more detailed
data are lacking on dispersal dynamics, demographic processes unde
10 s) are thought to be rising, but updated epidemiologic
data are lacking.
11 Reliable
data are lacking on pregnancy outcomes during Ebola virus disease
12 Long-term survival
data are lacking, and prognostic factors are not well defined.
13 ing the diagnosis and management of carcinoid heart
disease are lacking.
14 Effective drug treatments for many psychiatric
diseases are lacking, and the emerging tools and approaches outlined h
15 al studies and big-data approaches assessing sleep
dynamics are lacking.
16 o the cardiovascular system, data on their clinical
effects are lacking.
17 e understood, analyses examining their simultaneous
effects are lacking.
18 arkers of diabetic kidney disease (DKD) progression to
ESRD are lacking.
19 e in determining expansion speed but controlled
experiments are lacking.
20 e methylation data for low levels of prenatal lead
exposure are lacking.
21 study the health impacts of complex environmental
exposures are lacking.
22 Prognostic
factors are lacking in neurosarcoidosis (NS), and the association of
23 ools for immunofluorescence with small organic
fluorophores are lacking.
24 epidemiological studies focused on these terrestrial
frogs are lacking.
25 However, evidence-based
guidelines are lacking, and there is no consensus regarding which IVFs t
26 Direct comparisons of these novel treatments,
however,
are lacking.
27 cale evaluations of bacteriuria management among
inpatients are lacking.
28 Biomarkers of macronutrient
intake are lacking.
29 anslational models aimed at characterizing these
mechanisms are lacking.
30 re differences in severity of disease and clinical
outcomes are lacking.
31 However, results on long-term clinical
outcomes are lacking.
32 trials of secondary prevention treatment in MINOCA
patients are lacking.
33 tion.Reliable estimates of the total forest carbon (C)
pool are lacking due to insufficient information on dead organic m
34 cal models that mimic the natural stages of CRC
progression are lacking.
35 ncidence data on maternal GBS disease in developing
regions are lacking.
36 debated but studies that mimic a realistic in vivo
setting are lacking.
37 jective methods for identifying these ICU patient
subgroups are lacking.
38 vitamin D pathway on response to vitamin D
supplementation are lacking.
39 They revealed that the gene assemblies for
tailocins are lacking in these other bacteria.
40 ve tools to monitor the long treatment of tuberculosis (
TB)
are lacking.
41 eem more sensitive, high-quality evaluations of these
tests are lacking.
42 However, experimental tests of this cross-ecosystem
theory are lacking.
43 perfusion injury remain unresolved, and effective
therapies are lacking.
44 Preventive interventions post
trauma are lacking.
45 Currently, effective sepsis
treatments are lacking in the clinic, and care remains primarily support
46 in; however, clinical trials comparing these two
treatments are lacking.
47 n the 2001-2009 period, but data on recent incidence
trends are lacking.
48 onchopulmonary dysplasia, but appropriately designed
trials are lacking.
49 ate NETosis in an unbiased, reproducible, and efficient
way are lacking, considerably limiting the advancement of researc
50 sidues extending C-terminally from the globular core,
which are lacking in the Rad14 construct.